Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer

International Journal of Molecular Epidemiology and Genetics

Volumn 2, Issue 4, 2011, Pages 300-315

  Poole, Elizabeth M ^a,b,c   Curtin, Karen ^d   Hsu, Li ^a   Kulmacz, Richard J ^e   Duggan, David J ^f   Makar, Karen W ^a   Xiao, Liren ^a   Carlson, Christopher S ^a   Slattery, Martha L ^d   Caan, Bette J ^g   Potter, John D ^h   Ulrich, Cornelia M ^a,h,i  

^a Fred Hutchinson Cancer Research Center   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^g DIVISION OF RESEARCH   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Colorectal cancer; Colorectal polyps; EGFR; Genetics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; MICROSATELLITE DNA; PROSTAGLANDIN; PROTEIN TYROSINE KINASE;

ADULT; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CASE CONTROL STUDY; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; FEMALE; FOLLOW UP; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; PHENOTYPE; POINT MUTATION; PROSTAGLANDIN SYNTHESIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 83655211666     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004; 102: 37-46.
2. Cohen G, Mustafi R, Chumsangsri A, Little N, Nathanson J, Cerda S, Jagadeeswaran S, Dougherty U, Joseph L, Hart J, Yerian L, Tretiakova M, Yuan W, Obara P, Khare S, Sinicrope FA, Fichera A, Boss GR, Carroll R, Bissonnette M. Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. Cancer Res 2006; 66: 5656-64.
3. Malecka Panas E, Kordek R, Biernat W, Tureaud J, Liberski PP, Majumdar AP. Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. Hepatogastroenterology 1997; 44: 435-40.
4. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000; 21: 105-15.
5. Messa C, Russo F, Caruso MG, Di Leo A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998; 37: 285-9.
6. Tong WM, Ellinger A, Sheinin Y, Cross HS. Epidermal growth factor receptor expression in primary cultured human colorectal carcinoma cells. Br J Cancer 1998; 77: 1792-8.
7. Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD, Fidler IJ. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995; 1: 19-31.
8. Ng K, Zhu AX. Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hematol 2008; 65: 8-20.
9. Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ, Threadgill DW. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 2002; 99: 1521-6.
10. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000; 6: 1024-8.
11. Fichera A, Little N, Jagadeeswaran S, Dougherty U, Sehdev A, Mustafi R, Cerda S, Yuan W, Khare S, Tretiakova M, Gong C, Tallerico M, Cohen G, Joseph L, Hart J, Turner JR, Bissonnette M. Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res 2007; 67: 827-35.
12. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463-75.
13. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5: 63-9.
14. Vermeij J, Teugels E, Bourgain C, Xiangming J, Veld P, Ghislain V, Neyns B, De Greve J. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer 2008; 8: 3
15. Jaehne J, Urmacher C, Thaler HT, Friedlander Klar H, Cordon Cardo C, Meyer HJ. Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 1992; 118: 474-9.
16. Roskoski R Jr. The ErbB/HER receptor proteintyrosine kinases and cancer. Biochem Biophys Res Commun 2004; 319: 1-11.
17. Dehm SM, Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochem Cell Biol 2004; 82: 263-74.
18. Mathew S, George SP, Wang Y, Siddiqui MR, Srinivasan K, Tan L, Khurana S. Potential molecular mechanism for c-Src kinase-mediated regulation of intestinal cell migration. J Biol Chem 2008; 283: 22709-22.
19. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000; 19: 5636-42.
20. de Heer P, Koudijs MM, van de Velde CJ, Aalbers RI, Tollenaar RA, Putter H, Morreau J, van de Water B, Kuppen PJ. Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation. Eur J Surg Oncol 2008; 34: 1253-61.
21. Cartwright CA, Meisler AI, Eckhart W. Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci USA 1990; 87: 558-62.
22. Cartwright CA, Coad CA, Egbert BM. Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis. J Clin Invest 1994; 93: 509-15.
23. Press OA, Zhang W, Gordon MA, Yang D, Lurje G, Iqbal S, El Khoueiry A, Lenz HJ. Genderrelated survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res 2008; 68: 3037-42.
24. Goncalves A, Esteyries S, Taylor Smedra B, Lagarde A, Ayadi M, Monges G, Bertucci F, Esterni B, Delpero JR, Turrini O, Lelong B, Viens P, Borg JP, Birnbaum D, Olschwang S, Viret F. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer 2008; 8: 169
25. Gregorc V, Hidalgo M, Spreafico A, Cusatis G, Ludovini V, Ingersoll RG, Marsh S, Steinberg SM, Vigano MG, Ghio D, Villa E, Sparreboom A, Baker SD. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin Pharmacol Ther 2008; 83: 477-84.
26. Liu G, Gurubhagavatula S, Zhou W, Wang Z, Yeap BY, Asomaning K, Su L, Heist R, Lynch TJ, Christiani DC. Epidermal growth factor receptor polymorphisms and clinical outcomes in nonsmall-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 2008; 8: 129-38.
27. Brandt B, Hermann S, Straif K, Tidow N, Buerger H, Chang Claude J. Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. Cancer Res 2004; 64: 7-12.
28. Bandres E, Barricarte R, Cantero C, Honorato B, Malumbres R, Zarate R, Alcalde J, Garcia-Foncillas J. Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients. Oral Oncol 2007; 43: 713-9.
29. Nie Q, Wang Z, Zhang GC, An SJ, Lin JY, Guo AL, Li R, Gan B, Huang Y, Mok TS, Wu YL. The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib. Eur J Pharmacol 2007; 570: 175-81.
30. Siddig A, Mohamed AO, Kamal H, Awad S, Hassan AH, Zilahi E, Al Haj M, Bernsen R, Adem A. HER-2/neu Ile655Val polymorphism and the risk of breast cancer. Ann N Y Acad Sci 2008; 1138: 84-94.
31. Lee SC, Hou MF, Hsieh PC, Wu SH, Hou LA, Ma H, Tsai SM, Tsai LY. A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan. Clin Biochem 2008; 41: 121-5.
32. Millikan RC, Hummer AJ, Wolff MS, Hishida A, Begg CB. HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case-control analyses. Breast Cancer Res Treat 2005; 89: 309-12.
33. Nelson SE, Gould MN, Hampton JM, Trentham Dietz A. A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res 2005; 7: R357-64.
34. Cox DG, Hankinson SE, Hunter DJ. The erbB2/ HER2/neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet Genomics 2005; 15: 447-50.
35. Qu S, Cai Q, Gao YT, Lu W, Cai H, Su Y, Wang SE, Shu XO, Zheng W. ERBB2 genetic polymorphism and breast cancer risk in Chinese women: a population-based case-control study. Breast Cancer Res Treat 2008; 110: 169-76.
36. Potter JD, Bostick RM, Grandits GA, Fosdick L, Elmer P, Wood J, Grambsch P, Louis TA. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev 1996; 5: 779-84.
37. Slattery ML, Potter JD, Duncan DM, Berry TD. Dietary fats and colon cancer: assessment of risk associated with specific fatty acids. Int J Cancer 1997; 73: 670-7.
38. Slattery ML, Caan BJ, Benson J, Murtaugh M. Energy balance and rectal cancer: an evaluation of energy intake, energy expenditure, and body mass index. Nutr Cancer 2003; 46: 166-71.
39. Spirio LN, Samowitz W, Robertson J, Robertson M, Burt RW, Leppert M, White R. Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps. Nat Genet 1998; 20: 385-8.
40. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK, Slattery ML. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005; 129: 837-45.
41. Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, Slattery ML. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 2002; 99: 597-602.
42. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Relationship of Kiras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1193-7.
43. Slattery ML, Curtin K, Anderson K, Ma KN, Ballard L, Edwards S, Schaffer D, Potter J, Leppert M, Samowitz WS. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 2000; 92: 1831-6.
44. Samowitz WS, Albertsen H, Sweeney C, Herrick J, Caan BJ, Anderson KE, Wolff RK, Slattery ML. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 2006; 98: 1731-8.
45. Issa JP, Shen L, Toyota M. CIMP, at last. Gastroenterology 2005; 129: 1121-4.
46. Samowitz WS. The CpG island methylator phenotype in colorectal cancer. J Mol Diagn 2007; 9: 281-3.
47. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004; 74: 106-20.
48. Conneely KN, Boehnke M. So Many Correlated Tests, So Little Time! Rapid Adjustment of P Values for Multiple Correlated Tests. Am J Hum Genet 2007; 81: 1158-68.
49. Gauderman WJ, Murcray C, Gilliland F, Conti DV. Testing association between disease and multiple SNPs in a candidate gene. Genet Epidemiol 2007; 31: 383-95.
50. Slattery ML, Curtin K, Wolff RK, Boucher KM, Sweeney C, Edwards S, Caan BJ, Samowitz W. A comparison of colon and rectal somatic DNA alterations. Dis Colon Rectum 2009; 52: 1304-11.
51. Burton P, Gurrin L, Sly P. Extending the simple linear regression model to account for correlated responses: an introduction to generalized estimating equations and multi-level mixed modelling. Stat Med 1998; 17: 1261-91.
52. Kuss O, McLerran D. A note on the estimation of the multinomial logistic model with correlated responses in SAS. Comput Methods Programs Biomed 2007; 87: 262-9.
53. Chatterjee N, Kalaylioglu Z, Moslehi R, Peters U, Wacholder S. Powerful multilocus tests of genetic association in the presence of gene-gene and gene-environment interactions. Am J Hum Genet 2006; 79: 1002-16.
54. Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook EH Jr, Ratain MJ. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005; 65: 46-53.
55. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H, Eshima K. Differential gene expression signatures between colorectal cancers with and without KRAS mutations: Crosstalk between the KRAS pathway and other signalling pathways. Eur J Cancer 2011; 47: 1946-54.
56. Kuraoka K, Matsumura S, Hamai Y, Nakachi K, Imai K, Matsusaki K, Oue N, Ito R, Nakayama H, Yasui W. A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer. Int J Cancer 2003; 107: 593-6.
57. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999; 21: 187-90.
58. Laghi L, Bianchi P, Orbetegli O, Gennari L, Roncalli M, Malesci A. Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients. Br J Cancer 2001; 84: 196-8.
59. Daigo Y, Furukawa Y, Kawasoe T, Ishiguro H, Fujita M, Sugai S, Nakamori S, Liefers GJ, Tollenaar RA, van de Velde CJ, Nakamura Y. Absence of genetic alteration at codon 531 of the human c-src gene in 479 advanced colorectal cancers from Japanese and Caucasian patients. Cancer Res 1999; 59: 4222-4